Allergan Announces FDA Acceptance of Supplemental New Drug Application for AVYCAZ® (ceftazidime and avibactam)

DUBLIN, Nov. 20, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for AVYCAZ(®) (ceftazidime and avibactam), seeking to expand the label to include the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), in combination with metronidazole, in pediatric patients 3 months to less than 18 years of age.

The pediatric sNDA is based on two-active control clinical studies evaluating AVYCAZ in pediatric patients with cIAI or cUTI, as well as a single-dose pharmacokinetic study. In the cIAI study, the safety and efficacy of AVYCAZ (in combination with metronidazole) was compared with meropenem. In the cUTI study, AVYCAZ was compared with cefepime. Overall, the findings from the pediatric studies were similar to the previous determination of safety for AVYCAZ for the treatment of adult patients with cIAI or cUTI, and no new safety concerns were identified in pediatric patients. In addition, descriptive efficacy in the pediatric studies was consistent with data from studies in adults with cIAI and cUTI, and favorable clinical and microbiological responses were both observed against the predominant cIAI and cUTI pathogens.

"AVYCAZ has helped address the critical public health threat caused by difficult-to-treat Gram-negative pathogens," said David Nicholson, Chief Research & Development Officer at Allergan. "This sNDA filing acceptance is an important step towards expanding the availability of a potential treatment option to pediatric patients in need with cIAI and cUTI, including those infections caused by antibiotic-resistant pathogens."

AVYCAZ was first approved by the FDA in February 2015 for the treatment of cUTI including pyelonephritis, and cIAI in combination with metronidazole, caused by designated susceptible bacteria including certain Enterobacteriaceae and Pseudomonas aeruginosa, for patients 18 years of age and older. AVYCAZ was subsequently approved for the treatment of adults with hospital-acquired pneumonia/ventilator-associated pneumonia (HABP/VABP) caused by designated susceptible bacteria in February 2018.

About AVYCAZ(®) (ceftazidime and avibactam)

AVYCAZ is a fixed-dose combination antibacterial indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), cIAI (in combination with metronidazole), and cUTI caused by designated susceptible Gram-negative microorganisms in patients 18 years or older. AVYCAZ consists of a combination of avibactam and ceftazidime.

Avibactam is a first-in-class non-beta-lactam beta-lactamase inhibitor which protects ceftazidime against degradation by certain beta-lactamases. Avibactam does not decrease the activity of ceftazidime against ceftazidime-susceptible organisms. Ceftazadime is a third-generation cephalosporin with a well-established efficacy and safety profile.

AVYCAZ has demonstrated in vitro activity against Enterobacteriaceae in the presence of some beta-lactamases and extended-spectrum beta-lactamases (ESBLs) of the following groups: TEM, SHV, CTX-M, Klebsiella pneumoniae carbapenemase (KPCs), AmpC and certain oxacillinases (OXA). AVYCAZ also demonstrated in vitro activity against Pseudomonas aeruginosa in the presence of some AmpC beta-lactamases, and certain strains lacking outer membrane porin (OprD). AVYCAZ is not active against bacteria that produce metallo-beta lactamases and may not have activity against Gram-negative bacteria that overexpress efflux pumps or have porin mutations.

Ceftazidime and avibactam is being jointly developed with Pfizer. Allergan holds the rights to commercialize ceftazidime and avibactam in North America under the brand name AVYCAZ, while Pfizer holds the rights to commercialize the combination in the rest of the world under the brand name ZAVICEFTA®."

Complicated Intra-Abdominal Infections (cIAI)
AVYCAZ, in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter freundii complex, and Pseudomonas aeruginosa in patients 18 years or older.

Complicated Urinary Tract Infections (cUTI), including Pyelonephritis
AVYCAZ is indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter freundii complex, Proteus mirabilis, and Pseudomonas aeruginosa in patients 18 years or older.

Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP)
AVYCAZ(®) (ceftazidime and avibactam) is indicated for the treatment of HABP/VABP caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae in patients 18 years or older.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria.


AVYCAZ is contraindicated in patients with known serious hypersensitivity to the components of AVYCAZ (ceftazidime and avibactam), avibactam-containing products, or other members of the cephalosporin class.


    --  In a Phase 3 cIAI trial, clinical cure rates were lower in a subgroup of
        patients with baseline creatinine clearance (CrCl) of 30 to less than or
        equal to 50 mL/min compared to those with CrCl greater than 50 mL/min.
        The reduction in clinical cure rates was more marked in patients treated
        with AVYCAZ plus metronidazole compared to meropenem-treated patients.
        Within this subgroup, patients treated with AVYCAZ received a 33% lower
        daily dose than is currently recommended for patients with CrCl of 30 to
        less than or equal to 50 mL/min. Clinical cure rate in patients with
        normal renal function/mild renal impairment (CrCl greater than 50
        mL/min) was 85% (322/379) with AVYCAZ plus metronidazole vs 86%
        (321/373) with meropenem, and clinical cure rate in patients with
        moderate renal impairment (CrCl 30 to less than or equal to 50 mL/min)
        was 45% (14/31) with AVYCAZ plus metronidazole vs 74% (26/35) with
        meropenem. The decreased clinical response was not observed for patients
        with moderate renal impairment at baseline (CrCl 30 to less than or
        equal to 50 mL/min) in the Phase 3 cUTI trials or the Phase 3 HABP/VABP
        trial. Monitor CrCl at least daily in patients with changing renal
        function and adjust the dosage of AVYCAZ accordingly.
    --  Serious and occasionally fatal hypersensitivity (anaphylactic) reactions
        and serious skin reactions have been reported in patients receiving
        beta-lactam antibacterial drugs. Before therapy with AVYCAZ is
        instituted, careful inquiry about previous hypersensitivity reactions to
        other cephalosporins, penicillins, or carbapenems should be made.
        Exercise caution if this product is to be given to a penicillin or other
        beta-lactam-allergic patient because cross sensitivity among beta-lactam
        antibacterial drugs has been established. Discontinue the drug if an
        allergic reaction to AVYCAZ occurs.
    --  Clostridium difficile-associated diarrhea (CDAD) has been reported for
        nearly all systemic antibacterial drugs, including AVYCAZ, and may range
        in severity from mild diarrhea to fatal colitis. Careful medical history
        is necessary because CDAD has been reported to occur more than 2 months
        after the administration of antibacterial drugs. If CDAD is suspected or
        confirmed, antibacterials not directed against C. difficile should be
        discontinued, if possible.
    --  Seizures, nonconvulsive status epilepticus (NCSE), encephalopathy, coma,
        asterixis, neuromuscular excitability, and myoclonia have been reported
        in patients treated with ceftazidime, particularly in the setting of
        renal impairment. Adjust dosing based on CrCl.
    --  Prescribing AVYCAZ in the absence of a proven or strongly suspected
        bacterial infection is unlikely to provide benefit to the patient and
        increases the risk of the development of drug-resistant bacteria.

The most common adverse reactions in cIAI patients (>= 5% when used with metronidazole) were diarrhea (8%), nausea (7%), and vomiting (5%). The most common adverse reactions in cUTI patients (3%) were diarrhea and nausea. The most common adverse reactions in HABP/VABP patients (>= 5%) were diarrhea (15%) and vomiting (6%).

Please see the full Prescribing Information for AVYCAZ at

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS(®), on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.



Daphne Karydas
(862) 261-8006

Karina Calzadilla
(862) 261-7328

Amy Rose
(862) 289-3072

View original content to download multimedia:

SOURCE Allergan plc